aldesleukin
Last reviewed 01/2018
Aldesleukin, recombinant interleukin-2, is licensed for use in metastatic renal cell carcinoma at specialist centres. It does not increase longevity but can prompt tumour shrinkage in certain individuals. It is highly toxic, acute problems including pulmonary oedema and hypotension.